CAMPATH-IH in multiple sclerosis.
In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-IH which targets the CD52 antigen present on lymphocytes and monocytes. There was a substantial reduction in disease activity as measured by gadoliunium-enhancing lesions on MRI. Encouraged by this result a further se...
Príomhchruthaitheoirí: | Moreau, T, Coles, A, Wing, M, Thorpe, J, Miller, D, Moseley, I, Issacs, J, Hale, G, Clayton, D, Scolding, N, Waldmann, H, Compston, A |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
1996
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.
de réir: Moreau, T, et al.
Foilsithe / Cruthaithe: (1994) -
Inflammation, demyelination, and axonal degeneration: Three aspects of the pathogenesis of multiple sclerosis revealed by campath-1H treatment
de réir: Coles, A, et al.
Foilsithe / Cruthaithe: (2003) -
Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
de réir: Calne, R, et al.
Foilsithe / Cruthaithe: (1999) -
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.
de réir: Moreau, T, et al.
Foilsithe / Cruthaithe: (1996) -
CAMPATH: from concept to clinic.
de réir: Waldmann, H, et al.
Foilsithe / Cruthaithe: (2005)